Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

James Fisher delivers 'solid overall trading performance' in H2

(Sharecast News) - Marine engineering services firm James Fisher said on Wednesday that it had delivered a "solid overall trading performance" in H2 as its turnaround programme progressed as planned. James Fisher said its key end markets, particularly within the energy sector, remained supportive through H2, enabling it to deliver an "encouraging year-on-year revenue performance" in FY24.

The London-listed firm also stated its strategic turnaround initiatives had continued to deliver incremental improvements in profitability which, together with a contribution from several specific non-recurring items in the year, mean that it now expects the underlying operating profits to be roughly £29.0m in FY24, ahead of current market expectations.

Looking forward, whilst James Fisher said conditions in key end markets were expected to remain supportive in FY25, underpinned by structural drivers, it also said it remains mindful of continued near-term political and economic uncertainty.

Chief executive Jean Vernet said: "I am encouraged by our 2024 performance which will show underlying profit ahead of expectations together with an improved cash position. We ended the year in a stronger position having continued to execute on our turnaround strategy, including undertaking disposals and refinancing our debt facilities. As a result, we are now beginning to see the benefits of our transformation programme coming through.''

As of 0935 GMT, James Fisher shares were up 7.45% at 328.81p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.